DK3157552T3 - Syntac-polypeptider og anvendelser deraf - Google Patents

Syntac-polypeptider og anvendelser deraf Download PDF

Info

Publication number
DK3157552T3
DK3157552T3 DK15809277.5T DK15809277T DK3157552T3 DK 3157552 T3 DK3157552 T3 DK 3157552T3 DK 15809277 T DK15809277 T DK 15809277T DK 3157552 T3 DK3157552 T3 DK 3157552T3
Authority
DK
Denmark
Prior art keywords
applications
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
DK15809277.5T
Other languages
English (en)
Inventor
Rodolfo J Chaparro
Scott J Garforth
Steven C Almo
Ronald D Seidel Iii
Brandan S Hillerich
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Application granted granted Critical
Publication of DK3157552T3 publication Critical patent/DK3157552T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
DK15809277.5T 2014-06-18 2015-06-15 Syntac-polypeptider og anvendelser deraf DK3157552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
DK3157552T3 true DK3157552T3 (da) 2020-01-13

Family

ID=54936224

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18212801.7T DK3480213T3 (da) 2014-06-18 2015-06-15 Syntac-polypeptider og anvendelser deraf
DK15809277.5T DK3157552T3 (da) 2014-06-18 2015-06-15 Syntac-polypeptider og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18212801.7T DK3480213T3 (da) 2014-06-18 2015-06-15 Syntac-polypeptider og anvendelser deraf

Country Status (17)

Country Link
US (5) US20170058015A1 (da)
EP (3) EP3157552B1 (da)
JP (4) JP6652932B2 (da)
KR (1) KR102252119B1 (da)
CN (3) CN113248623A (da)
AU (3) AU2015277460B2 (da)
BR (1) BR112016027897A2 (da)
CA (1) CA2947489A1 (da)
DK (2) DK3480213T3 (da)
ES (2) ES2770330T3 (da)
HU (2) HUE047255T2 (da)
IL (3) IL248979B (da)
PL (2) PL3480213T3 (da)
PT (2) PT3157552T (da)
SG (2) SG11201609876TA (da)
TW (3) TWI696633B (da)
WO (1) WO2015195531A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
US20190062400A1 (en) * 2016-03-02 2019-02-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) * 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190019068A (ko) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
IL266696B2 (en) * 2016-12-22 2023-04-01 Cue Biopharma Inc Multimeric polypeptides modulate t cells and methods for their use
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2018187190A1 (en) * 2017-04-06 2018-10-11 Albert Einstein College Of Medicine, Inc. Precision activation of hiv-specific ctls to eliminate reactived latent t cells
KR20200016954A (ko) * 2017-06-12 2020-02-17 시나이 헬스 시스템 전신 면역억제가 불필요한 동종 이식편 내성
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. ANTIGEN PRESENTATION POLYPEPTIDES AND THEIR METHODS OF USE
CA3070484A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
KR20200064085A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3512874A2 (en) * 2017-11-30 2019-07-24 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
RU2020131383A (ru) 2018-03-24 2022-04-26 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные животные, отличные от человека, для выработки терапевтических антител против комплексов пептид-mhc, способы их получения и варианты применения
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
AU2019401183A1 (en) * 2018-12-19 2021-08-12 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
TW202039542A (zh) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
CN114126635A (zh) * 2019-05-29 2022-03-01 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2022003367A (es) * 2019-09-20 2022-04-11 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t y metodos de uso de estos.
CA3146917A1 (en) * 2019-10-23 2021-04-29 Anish SURI T-cell modulatory chimeric molecules and methods of use thereof
AU2020407233A1 (en) 2019-12-20 2022-08-18 Regeneron Pharmaceuticals, Inc. Novel IL2 agonists and methods of use thereof
WO2021168122A1 (en) * 2020-02-18 2021-08-26 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
EP4149953A1 (en) * 2020-05-12 2023-03-22 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
WO2022236102A1 (en) * 2021-05-07 2022-11-10 Institute For Systems Biology Single chain trimer mhc class i nucleic acids and proteins and methods of use
WO2023022965A2 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
WO2023205728A2 (en) * 2022-04-21 2023-10-26 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
RU2162342C2 (ru) 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
AU2002240818C1 (en) * 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
MX354660B (es) 2012-11-30 2018-03-14 Roche Glycart Ag Remocion de las celulas de cancer por celulas t citotoxicas, especificas de virus, en circulacion, usando proteinas multifuncionales que comprenden complejo de histocompatilibidad principal (mhc) clase i, dirigidas a celulas de cancer.

Also Published As

Publication number Publication date
PL3157552T3 (pl) 2020-05-18
JP2020022491A (ja) 2020-02-13
EP3157552B1 (en) 2019-10-23
TWI795740B (zh) 2023-03-11
PT3157552T (pt) 2020-01-22
JP7331075B2 (ja) 2023-08-22
WO2015195531A2 (en) 2015-12-23
EP3157552A2 (en) 2017-04-26
CA2947489A1 (en) 2015-12-23
TWI722576B (zh) 2021-03-21
KR102252119B1 (ko) 2021-05-17
AU2021204594A1 (en) 2021-07-29
JP2017519491A (ja) 2017-07-20
EP3480213B1 (en) 2019-11-13
JP2022046544A (ja) 2022-03-23
TWI696633B (zh) 2020-06-21
EP3483179A1 (en) 2019-05-15
IL248979A0 (en) 2017-01-31
WO2015195531A3 (en) 2016-02-25
BR112016027897A2 (pt) 2017-10-24
IL248979B (en) 2020-06-30
KR20170030484A (ko) 2017-03-17
CN106456733A (zh) 2017-02-22
CN106456733B (zh) 2021-03-16
AU2015277460A1 (en) 2016-11-24
TW202124435A (zh) 2021-07-01
TW201613966A (en) 2016-04-16
SG11201609876TA (en) 2017-01-27
JP2020072733A (ja) 2020-05-14
IL275307B (en) 2022-03-01
US20200377569A1 (en) 2020-12-03
TW201946933A (zh) 2019-12-16
EP3483179B1 (en) 2020-09-16
IL266570A (en) 2019-07-31
US20210047384A1 (en) 2021-02-18
PT3480213T (pt) 2020-02-04
JP6652680B2 (ja) 2020-02-26
US20210238254A1 (en) 2021-08-05
HUE047255T2 (hu) 2020-04-28
SG10202006338UA (en) 2020-08-28
DK3480213T3 (da) 2020-02-17
PL3480213T3 (pl) 2020-05-18
JP6652932B2 (ja) 2020-02-26
AU2019203442B2 (en) 2021-04-08
AU2019203442A1 (en) 2019-06-06
US20170058015A1 (en) 2017-03-02
AU2015277460B2 (en) 2020-10-08
HUE048076T2 (hu) 2020-07-28
JP6995151B2 (ja) 2022-02-21
ES2767259T3 (es) 2020-06-17
CN113248623A (zh) 2021-08-13
IL275307A (en) 2020-07-30
EP3157552A4 (en) 2017-11-22
IL266570B (en) 2020-06-30
ES2770330T3 (es) 2020-07-01
EP3480213A1 (en) 2019-05-08
CN113248624A (zh) 2021-08-13
US20180282392A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3302431T3 (da) Taxanpartikler og anvendelse deraf
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3224603T3 (da) Nordning og fremgangsmåde til materialekarakteristik
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK4089113T3 (da) Polypeptider
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf